(-0.02%) 5 212.50 points
(-0.03%) 39 015 points
(-0.03%) 18 194 points
(-0.55%) $77.95
(0.36%) $2.22
(0.08%) $2 326.00
(0.24%) $27.61
(-0.12%) $987.20
(0.14%) $0.931
(0.40%) $10.94
(0.19%) $0.801
(0.04%) $91.48
Quarter results tomorrow
(bmo 2024-05-09)
Expected move: +/- 0.00%
0.88% € 366.60
Live Chart Being Loaded With Signals
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France...
Stats | |
---|---|
Dzisiejszy wolumen | 45 751.00 |
Średni wolumen | 56 834.00 |
Kapitalizacja rynkowa | 21.79B |
EPS | €0 ( 2024-02-28 ) |
Następna data zysków | ( €-0.750 ) 2024-05-09 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -76.38 |
ATR14 | €0.274 (0.07%) |
Wolumen Korelacja
argenx SE Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
argenx SE Korelacja - Waluta/Towar
argenx SE Finanse
Annual | 2023 |
Przychody: | €1.13B |
Zysk brutto: | €925.50M (81.59 %) |
EPS: | €-4.77 |
FY | 2023 |
Przychody: | €1.13B |
Zysk brutto: | €925.50M (81.59 %) |
EPS: | €-4.77 |
FY | 2022 |
Przychody: | €410.75M |
Zysk brutto: | €381.32M (92.83 %) |
EPS: | €-13.05 |
FY | 2021 |
Przychody: | €497.28M |
Zysk brutto: | €0.00 (0.00 %) |
EPS: | €-8.99 |
Financial Reports:
No articles found.
argenx SE
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej